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Abstract
Background: HIV-1-infected and/or immune-activated microglia and macrophages are pivotal in the pathogenesis
of HIV-1-associated neurocognitive disorders (HAND). Glutaminase, a metabolic enzyme that facilitates glutamate
generation, is upregulated and may play a pathogenic role in HAND. Our previous studies have demonstrated that
glutaminase is released to the extracellular fluid during HIV-1 infection and neuroinflammation. However, key
molecular mechanisms that regulate glutaminase release remain unknown. Recent advances in understanding
intercellular trafficking have identified microvesicles (MVs) as a novel means of shedding cellular contents. We
posit that during HIV-1 infection and immune activation, microvesicles may mediate glutaminase release,
generating excessive and neurotoxic levels of glutamate.
Results: MVs isolated through differential centrifugation from cell-free supernatants of monocyte-derived macrophages
(MDM) and BV2 microglia cell lines were first confirmed in electron microscopy and immunoblotting. As expected, we
found elevated number of MVs, glutaminase immunoreactivities, as well as glutaminase enzyme activity in the
supernatants of HIV-1 infected MDM and lipopolysaccharide (LPS)-activated microglia when compared with
controls. The elevated glutaminase was blocked by GW4869, a neutral sphingomyelinase inhibitor known to
inhibit MVs release, suggesting a critical role of MVs in mediating glutaminase release. More importantly, MVs
from HIV-1-infected MDM and LPS-activated microglia induced significant neuronal injury in rat cortical neuron cultures.
The MV neurotoxicity was blocked by a glutaminase inhibitor or GW4869, suggesting that the neurotoxic potential of
HIV-1-infected MDM and LPS-activated microglia is dependent on the glutaminase-containing MVs.
Conclusions: These findings support MVs as a potential pathway/mechanism of excessive glutamate generation and
neurotoxicity in HAND and therefore MVs may serve as a novel therapeutic target.
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Background
HIV-1-associated neurocognitive disorders (HAND) are
currently prevalent in spite of major advances in combin-
ation anti-retroviral therapy. Therefore, novel therapeutic
targets are required to be developed to treat the disease
[1–4]. The HIV-1-infected and immune-activated mono-
nuclear phagocytes (MPs, including macrophages and
microglia) are critical to HAND pathogenesis, producing
a variety of inflammatory and neurotoxic factors, includ-
ing excess levels of the excitatory neurotransmitter glu-
tamate [5, 6]. Glutamate is a major mediator of excitatory
synaptic transmission and has a vital role in mediating
learning and memory [7–9]. Early studies reported that
the concentrations of glutamate in the plasma and cere-
brospinal fluid were significantly higher in HIV-1-infected
patients than in uninfected controls [10–13]. Studies also
showed that excessive levels of extracellular glutamate in-
duce excitotoxicity and augment neuroinflammation and
neuronal injury, which may play a role in the pathogenesis
of HAND [14–19].
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Glutaminase (GLS), a resident mitochondria enzyme,
is specialized in the de novo synthesis of the neurotrans-
mitter glutamate [20–24]. Two major types of GLS exist
in mammals, which include “kidney-type” (GLS1) and
“liver-type” (GLS2) transcribed from different genes.
GLS has also been found to be abundant in the brain tis-
sue [15]. In human brain, GLS1 has two allozymes:
kidney-type glutaminase (KGA) [25] and glutaminase C
(GAC) [26]. The allozymes are generated through tissue-
specific alternative splicing from the same gene and have
the identical core GLS1 enzyme domain but different 3′
tails [27]. Our previous studies suggested that GAC and
KGA are differentially upregulated in HAND brain
samples, HIV-1-infected MPs and inflammatory neu-
rons [6, 28–31]. Increased extracellular levels of glu-
tamate from activated MPs could cause excitotoxicity
to neurons through NMDA receptor activation [28, 29].
Therefore, regulation of GLS1 isoforms is of import-
ance to HAND research. A key molecular event associ-
ated with the elevation of glutamate is the release of
GLS1 [28, 30, 31]. Although several early observations
of GLS1 release were linked with cell death, more recent
data from our lab suggested that mitochondrial stress could
lead to membrane destabilization and relocation of GLS1
from the mitochondrial matrix to the cytosol through the
permeability transition pore [32]. Because further release of
GLS1 into extracellular supernatants contributes to excess
glutamate production, it is imperative to understand the
molecular mechanism of cellular GLS1 release.
Recent evidence indicates that microvesicles (MVs), un-
conventional cellular secretory vesicles, are shed from the
plasma membrane and range from 100 nm to 1 μm in
diameter [33]. Interestingly, MVs are abundant in the cen-
tral nervous system (CNS) and are derived from multiple
brain cell types, including neurons, microglia, oliogoden-
drocytes, and astrocytes [34]. Therefore, there is a growing
appreciation of the important role of MVs in regulating the
brain microenvironment [35, 36]. CNS-derived MVs may
contribute to neuroinflammation through secretion of sig-
naling molecules, nucleic acids, lipids, and proteins, and
may participate in inter- and intra-cellular communication
[33, 37–42]. Release of MVs is increased upon neural can-
cer progression, neuroinflammation, and acute neurological
disorders. MVs could serve as a useful biomarker for CNS
diseases including ischemic stroke, multiple sclerosis, glio-
blastoma, and other neurological and neurodegenerative
disorders [43–45]. However, the role of MVs in the patho-
genesis of neurodegenerative disorders, especially HAND,
remains to be elucidated. In our current study, we iden-
tified MVs as a primary mechanism of GLS1 release,
which subsequently mediates excess glutamate generation
and neurotoxicity from HIV-1-infected macrophages and
immune-activated microglia. The investigation of the
function of GLS1-containing MVs is important for
understanding a potentially pathological event in HAND,
and it may provide possible therapeutic targets and a
unique biomarker.
Results
HIV-1 infection and immune activation increase MV
release from macrophages and microglia
Our previous studies have demonstrated that GLS1 is re-
leased to the extracellular fluid during HIV-1 infection and
neuroinflammation [28, 30, 31]. However, key molecular
mechanisms that regulate GLS1 release remain unknown.
Recent discovery of MVs during HIV-1 infection in macro-
phages and dendritic cells offers an exciting possibility that
GLS1 may be released through MV mechanism [33, 46].
We used scanning electron microscopy (SEM) to identify
MVs that were in the process of budding from macro-
phages (Fig. 1a, b). To quantitatively evaluate MVs release,
two different techniques for MV detection were used.
First, MVs were isolated from cultured monocyte-derived
macrophages (MDM) supernatants by differential centrifu-
gation. To reflect the changes of MVs from same number
of cells, MVs were isolated from normalized volumes of
supernatants based on the protein concentrations in the
whole cell lysates. Cells, nuclei, debris and subcellular or-
ganelles were removed from supernatant after serial cen-
trifugation. The MV pellet was collected and resuspended
for negative staining under transmission electron micros-
copy (TEM). Images of MVs from ten random fields were
captured. The numbers of MVs per field under TEM was
significantly higher in HIV-1-infected macrophages than
MVs from mock-infected macrophages, suggesting that
HIV-1 infection leads to increased release of MVs in
MDM (Fig. 1c-e). Similarly, when murine microglia cell
line BV2 was treated with lipopolysaccharide (LPS) for im-
mune activation, the MV number was significantly higher
in the LPS-treated BV2 compared with the untreated
group (Fig. 1f-h). Second, MVs isolated from infected hu-
man macrophages and immune activated microglia were
subjected to Western blots for specific MV markers, in-
cluding ALG-2 interacting protein (Alix) and flotillin-2.
Consistent with TEM data, Western blot analysis revealed
increased levels of Alix and flotillin-2 in MV lysates from
HIV-1-infected cells, compared with those from unin-
fected cultures (Fig. 1i). The increased release of MVs from
LPS-treated BV2 cells was further confirmed in Western
blot by MV markers, Alix and flotillin-2 (Fig. 1j). Because
MVs were isolated from normalized volumes of superna-
tants based on their corresponding whole cell protein con-
centrations, higher number of MVs in TEM and increased
immunoreactivities of MV markers in Western blots from
HIV-1-infected macrophages and LPS-stimulated micro-
glia suggest that HIV-1 infection and immune activation
both increase MV release from the cultures.
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MVs mediate GLS1 release in HIV-1-infected MDM and
immune-activated microglia
To determine whether MVs are the main mechanism for
GLS1 release in HIV-1-infected MDM and immune-
activated microglia, we treated the cultures with GW4869,
a neutral sphingomyelinases (nSMase) inhibitor, for 24 h
prior to MVs isolation. GW4869 is known to disrupt in the
biogenesis of MVs [47, 48]. Because GW4869 was dis-
solved in DMSO, we used DMSO as a solvent control
for GW4869 and used same amount of DMSO in each
dose of the GW4869 treatment. MV markers, Alix and
flotillin-2, were both increased in the MVs isolated from
HIV-1-infected MDM (Fig. 2a-c). Pretreatment with
GW4869 for 24 h reduced the levels of Alix and
flotillin-2 in the MVs isolated from HIV-1-infected
MDM, indicating the increased MV release in HIV-1-
infected MDM could be blocked by GW4869 (Fig. 2a-c).
The protein levels of GAC, a GLS1 isoform previously
identified to have neurotoxic potential, were also in-
creased in MVs after HIV-1 infection and diminished
Fig. 1 HIV-1 infection and immune activation increase MVs release from macrophages and microglia. a MDM were fixed at 7th day post HIV-1 infection
and subsequently subjected to SEM for MV detection. Magnification, 6000 ×. c High-magnification image of the corresponding small box area in panel
A was shown. Magnification, 24000 ×. c-h MVs were isolated through differential centrifugation from normalized volumes of cultural supernatants and
observed under TEM using negative staining. Representative TEM images of MVs from mock-infected MDM (c), HIV-1 infected MDM (d),
untreated microglia (f), and LPS-stimulated microglia (g) were shown. e, h MVs numbers in c, d and e, f were quantified by manually
counting from a total of 10 random vision fields. Results are representative of TEM images and quantification results are means ± SD
of MV numbers from 10 fields of TEM images. ** denotes p < 0.01 in comparison to controls. i, j MVs were isolated from normalized
volumes of supernatants in mock-infected and HIV-1-infected MDM cultures (i) or untreated and LPS-stimulated microglia cultures (j).
The levels of Alix and flotillin-2 in MVs were determined by Western blot
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after GW4869 treatment, indicating that MVs carried
GAC as cargo and that HIV-1 increases GAC release
through MVs (Fig. 2a, d). Consistent with HIV-1 infection,
LPS activation of microglia line BV2 cells also lead to in-
creased MV secretion (Fig. 2e-g). After treatment with in-
creasing concentrations of GW4869, the increase of Alix
and Flotillin-2 in the MVs isolated from LPS-activated
microglia was blocked, suggesting that immune activation
also increases MV release in microglia (Fig. 2e-g). Import-
antly, GAC protein levels were also increased in MVs after
LPS activation and diminished after GW4869 treatment,
confirming that immune activation also increases GAC re-
lease through MVs (Fig. 2e, h).
MVs isolated from HIV-1-infected MDM and immune-
activated microglia mediate extracellular glutamate pro-
duction through GLS1
The identification of MVs in mediating GAC release raises
the question of functional relevance of GAC to MVs. HIV-
1 infection is known to increase extracellular levels of glu-
tamate in human macrophages [2]. We treated cell-free
HIV-1-infected supernatants with 5 mM glutamine, the re-
action substrate for GLS enzyme, in the presence of 6-
Diazo-5-oxo-L-norleucine (L-DON), a GLS1 inhibitor.
The levels of glutamate production, as determined by
RP-HPLC, increased after HIV-1 infection, which was
dependent on glutamine (Fig. 3a). Furthermore, the ele-
vation of glutamate was blocked by L-DON, indicating
that the released GLS1 promotes glutamate generation in
the extracellular fluid of HIV-1-infected MDM (Fig. 3a).
More importantly, MV pellets extracted from both mock-
and HIV-1-infected MDM were directly tested for GLS
activity by HPLC. MVs were incubated with neurobasal
media with or without glutamine for two days. Interest-
ingly, the levels of glutamate generated in MVs from HIV-
1-infected cultures elevated significantly compared with
mock-infected control (Fig. 3b). Low speed pellets were
collected after 10,000 g centrifugation, which may contain
subcellular organelles and debris. Interestingly, blockage
of GLS1 activity by L-DON was only observed in the MVs
but not in the low speed pellets from HIV-1-infected
MDM, suggesting that MVs are the specific compartments
for GLS1 release and responsible for excess glutamate
production (Fig. 3b). Consistent with HIV-1-infected
MDM, MVs isolated from supernatant of LPS-stimulated
microglia significantly increased glutamate generation,
which could be blocked by L-DON (Fig. 3c). To fur-
ther investigate how MVs facilitate glutamine hydrolysis
through the GLS1, we determined the level of vesicular glu-
tamate transporter (VGLUT) in the MV lysates from HIV-
1 infected MDM through Western blots (Additional file 1:
Figure S1). VGLUT levels increased after HIV-1 infection
and decreased after GW4869 treatment, consistent with
the overall MV levels. These results indicate VGLUT is a
component of MVs and suggest that glutamate transporters
on the MV lipid bilayer may facilitate the transporta-
tion of glutamate. Taken together, these data suggest that
GLS1 released through MVs in HIV-1-infected MDM and
Fig. 2 MVs mediate GLS1 release in HIV-1-infected MDM and immune-activated microglia. a At 7 days post-infection, mock-infected and HIV-1 infected
MDM were treated with GW4869 for 24 h in serum-free media. MVs were isolated from the supernatants and MV protein lysates were prepared. The levels
of Alix, flotillin-2, and GAC were determined by Western blots. b, c, d Densitometric quantifications of the Alix (b), flotillin-2 (c), and GAC (d) protein levels
were presented as fold change relative to the mock-infected controls. e MVs were isolated from the supernatants of control and LPS-treated microglia in
the presence and absence of GW4869. MV lysates were subjected to Alix, flotillin-2, and GAC detection through Western blots. Results shown
are representative of three independent experiments. f, g, h Densitometric quantifications of the Alix (f), flotillin-2 (g), and GAC (h) protein levels were
presented as fold change relative to the untreated controls. DMSO was used as solvent control for GW4869. Western blot results shown are representative
of three independent experiments. Quantification results shown are means ± SD of experiments performed in triplicate (n= 3 donors). ** and *** denotes
p< 0.01 and 0.001 in comparison to mock-infected or untreated control; #, ## and ### denote p < 0.05, 0.01 and 0.001 in comparison to HIV-infected or
immune-activated groups, respectively
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immune-activated microglia maintains enzyme activity
and promotes glutamate generation.
GLS1-containing MVs induce neurotoxicity
To investigate the functional significance of GLS1-
containing MVs from HIV-1-infected MDM and immune-
activated microglia, MVs were collected and re-suspended
in neuronal culture medium. The volumes of culture
medium used to re-suspend MVs were adjusted based on
the whole cell protein concentration in the same culture.
Rat cortical neurons (RCN) treated with 10 μl or 100 μl
per well of MVs from HIV-1-infected MDM had signifi-
cantly lower viabilities (Fig. 4a) and higher neurotoxicity
(Fig. 4c) compared with those treated with MVs from
mock-infected cells. However, the MV-induced toxicity
was rescued at the presence of BPTES, a GLS1 inhibitor,
when 100 μl of MVs were incubated with RCN (Fig. 4b, d).
Similar neurotoxicity was observed in neurons treated with
MVs isolated from LPS-activated microglia (Fig. 4e), an ef-
fect that was blocked by BPTES (Fig. 4f). These data sug-
gest that the GLS1-containing MVs induce neurotoxicity
through the GLS1 activity in the MVs.
HIV-1-infected MDM induce neurotoxicity through GLS1-
containing MVs
To determine whether HIV-1-infected MDM induce
neurotoxicity through GLS1-containing MVs, we ob-
tained supernatants from HIV-1-infected macrophages
that were pre-treated with 2, 5 or 10 μM of GW4869 and
used the supernatants to treat RCN for neurotoxicity. Simi-
lar with prior experiments, we used DMSO as a solvent
control for GW4869 and used same amount of DMSO in
each dose of the GW4869 treatment. Neurotoxicity was de-
termined through quantifications of neuronal antigen
MAP2 with either MAP2 ELISA (Fig. 5a) or MAP2
immunostaining (Fig. 5b, Additional file 2: Figure S2). The
HIV-1-infected MDM-induced neurotoxicity was blocked
by increasing concentrations of GW4869 (Fig. 5a b), indi-
cating that supernatants from HIV-1-infected MDM induce
neurotoxicity through MVs. Next, we isolated MVs from
mock-infected and HIV-1-infected MDM and investigated
the direct neurotoxicity of MVs. Interestingly, MVs isolated
from HIV-1-infected MDM manifested higher levels of
neurotoxicity as determined by MAP2 ELISA (Fig. 5i) or
MAP2 immunostaining (Fig. 5c-h, j), when compared with
MVs from mock-infected control. Treatment of GW4869
prior to MV isolation rescued MV-induced neurotoxicity
at a dose dependent manner, suggesting a direct neurotoxic
role of MVs from HIV-1-infected MDM. Together, these
data strongly suggest that HIV-1-infected macrophages in-
duce neurotoxicity through MVs.
Discussion
Our previous reports have described the release of GLS1
into extracellular space during neuroinflammation or
HIV-1 infection. However, key molecular mechanisms
that regulate GLS1 release remain unknown. Our current
study presents two important new findings regarding GLS1
release. First, MVs contain GLS1, which is a key enzyme
for generating glutamate in the brain, and GLS1 is released
into the extracellular fluid primarily via MVs in HIV-1-
infected cells and immune-activated microglia. Second,
HIV-1 infection and LPS activation increase the magnitude
of MV release from macrophages and microglia. Interest-
ingly, increased release of GLS1-containing MVs also in-
duces excitotoxicity in RCN. The toxic effect of MVs was
reversed by glutaminase inhibitors and MV inhibitors.
These observations suggest that MVs may contribute to ex-
cess glutamate production in macrophages in the context
of HIV-1 neurotoxicity.
Fig. 3 MVs isolated from HIV-1-infected MDM and immune-activated microglia mediate extracellular glutamate production through GLS1. a Cell-free
supernatants from mock-infected and HIV-1-infected macrophages were incubated with or without glutamine and 1 mM L-DON ex vivo for two days.
The resulting glutamate levels were determined by RP-HPLC. *** denotes p < 0.001 in comparison to the 5 mM glutamine group in HIV-1-infected
samples. b MVs were isolated from cell-free supernatants from mock-infected and HIV-1-infected MDM and incubated with or without glutamine and
1 mM L-DON ex vivo for two days. Glutamate generation in MVs or low speed (LS) pellets was determined by RP-HPLC. Low speed pellets were collected
after 10,000 g centrifugation, which contained subcellular organelles and debris. *** denotes p< 0.001 in comparison to 5 mM glutamine group in HIV-1-
infected samples. c MVs were isolated from cell-free supernatants from untreated and LPS-activated microglia and incubated with or without glutamine
and 1 mM L-DON ex vivo for two days. Glutamate generation in MVs was determined by RP-HPLC. *** denotes p< 0.001 in comparison to 5 mM glutamine
group in LPS-activated samples. Results are means ± SD of triplicate samples and are representative of three independent experiments
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The physiological relevance of this observation is sig-
nificant, where elevated endogenous levels of GLS1 have
been reported in the post mortem brain tissues of HIV-1-
associated dementia patients [29, 49]. Furthermore, it has
been demonstrated that both of the upregulated GLS1 iso-
forms, KGA and GAC, are released from the inner mem-
brane of mitochondria into the cytosol through the
permeability transition pore [31, 32]. However, it is the
extracellular glutamate that causes neurotoxicity, and the
mechanisms by which cytosolic GLS1 is released into
the cell supernatant have not been previously estab-
lished. The current study provides strong evidence that
GLS1-containing MVs are the main mechanism for the
release of GLS1 from the macrophage and microglia
cytosol into the extracellular compartment, where the
extracellular glutamate subsequently induces neurotox-
icity. It is unclear how GLS1 hydrolyzes extracellular
glutamine inside MVs. We have detected vesicular glu-
tamate transporter in the MV lysates from HIV-1 in-
fected MDM (Additional file 1: Figure S1), suggesting
that MVs may transport glutamate across its lipid bi-
layer through glutamate transporters.
Our studies were designed to rigorously establish the
purity and characterization of the isolated microvesicles.
To confirm complete separation of MVs from mitochon-
dria, the absence of the mitochondrial marker protein
voltage-dependent anion-selective channel and cytochrome
C was confirmed through Western blots (data not shown).
Fig. 4 GLS1-containing MVs induce neurotoxicity. a-d Extracellular MVs were isolated from mock-infected and HIV-1-infected MDM at 7 days
post-infection and incubated with RCN at the indicated dosage for 24 h (a, c). 100 μl of MVs were added in RCN with or without 10 μM of BPTES, a
GLS1 inhibitor, for 24 h (b, d). Neurotoxic potentials of MVs were determined by MTT (a, b) and MAP2 ELISA assays (c, d). e, f Extracellular MVs were isolated
from control and LPS-activated microglia and incubated with RCN with or without 10 μM of BPTES for 24 h. Neurotoxic potentials of MVs were determined
by MTT with incubation of different dosages of MVs (e) and MAP2 ELISA assays with incubation of 100 μl of MVs (f). *, ** and *** denote
p < 0.05, 0.01 and 0.001 in comparison to controls, respectively; #, ## and ### denote p < 0.05, 0.01 and 0.001 in comparison to HIV-infected group,
respectively. Results are expressed as means ± SD of triplicate samples and are representative of three independent experiments
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Secondly, to characterize the MVs, both scanning and
transmission electron microscopies were used, which
showed vesicles ranging in size from 100 nm to 500 nm.
Western blot could not detect the presence of GLS1 in exo-
somes collected from commercially available exosome kits,
suggesting that GLS1 is selectively packed into MVs rather
than into smaller exosomes. Furthermore, because the MV-
free supernatants and the pellets that contained cellular
debris had minimum GLS activities and GLS1 was found
predominantly in the isolated MVs fraction, we concluded
that MVs are the primary instigator in facilitating GLS1 re-
lease in HIV-1-infected macrophages and LPS-activated
microglia. Chronic activation of the immune system is a
hallmark of progressive HIV infection yet its etiology re-
mains obscure. Circulating microbial products such as LPS,
possibly derived from the gastrointestinal tract, was signifi-
cantly increased in chronically HIV-infected individuals and
may be a cause of HIV-related systemic immune activation
[50]. In our report, when LPS was used to treat BV2 micro-
glia cell line, high levels of GLS1 were found in the
Fig. 5 HIV-1-infected macrophages induce neurotoxicity through GLS1-containing MVs. At 7 days post-infection, mock-infected and HIV-1 infected
macrophages were treated with GW4869 at different dosages for 24 h. Cell-free supernatants and MVs were collected and added to RCN cultures
for neurotoxicity. DMSO was used as solvent control for GW4869. a, b Neurotoxic potentials of the supernatants were determined by MAP2 ELISA
assay (a) and quantification of MAP2 fluorescence in immunostaining (b). c-j Neurotoxic potentials of MVs were determined by MAP2 ELISA assay
(i) and immunostaining (c-h) followed by quantification of the intensity of MAP2 fluorescence after MVs treatment. NM in panels A and I stands
for neuronal media. * and *** denote p < 0.05 and 0.001 in comparison to mock-treated control, respectively; ## and ### denote p < 0.01 and 0.001 in
comparison to DMSO-pretreated HIV-infected group, respectively. Results are expressed as means ± SD of triplicate samples and are representative of
three independent experiments
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supernatants leading to neurotoxicity. These results support
the pathogenic effect of the immune activation in the
CNS during HIV-1 infection. The discovery that im-
mune activation induces GLS1 release via MVs may have a
broader implication to other neurological diseases, where
excitotoxicity and GLS1 are involved. Because MVs are
abundantly expressed in the CNS, it is tempting to
speculate whether qualitative or quantitative changes of
MVs contribute more broadly to neurological diseases.
In addition, the regulation of MVs could be exploited
as a novel therapeutic target.
In the current study, we also utilized a MV inhibitor,
GW4869, to block the release of the MVs. Both GLS1 and
MV markers were decreased in a dose-dependent manner
by GW4869, suggesting that GLS1 release is through MVs.
GW4869 is an inhibitor for nSMase2, which is responsible
for the production of ceramide. Ceramide has been found
enriched in MVs and involved in the formation of vesicles.
Our results point to a possible mechanism of MVs release
in the microglia and macrophages through the endosomal
sorting complex required for transport (ESCRT) machinery
or a ceramide-dependent pathway [47, 48, 51]. These inter-
esting possibilities remain the subject of future investiga-
tion. Furthermore, we have demonstrated that the
neurotoxicity by HIV-1-infected MDM was abolished
by pre-treatment with GW4869, which indicates that
GLS1-containing MVs are the neurotoxic factors in HIV-
1-infected macrophages and immune-activated microglia.
Therefore, inhibiting the release of MVs might become a
potential therapeutic approach for the treatment of HAND
patients.
Three aspects of the studies merit further investiga-
tion. First, how is cytosolic GLS1 loaded into MVs for
extracellular secretion from macrophages? Second, how are
GLS1-containing MVs formed? Third, what mediates the
release of GLS1-containing MVs from the plasma mem-
brane? Autophagosomes, inflammasomes or mitochondria-
derived vesicles may provide possible mechanisms for these
events to occur. It is possible that HIV-1 infection and im-
mune activation of macrophages and microglia directly
lead to release of GLS1-containing MVs, however, other
possibilities also need to be explored.
Conclusions
In summary, our studies address important questions re-
garding the cellular mechanisms of GLS1 release, impli-
cating a critical role of MVs. This newfound knowledge
of neurotoxic GLS1-containing MVs has potentially im-
portant clinical implications for neurologic diseases such
as HAND. Developing inhibitors of MV formation and
release or inhibitors of GLS1 might yield effective new
therapies for reducing glutamate-induced neurotoxicity
in HIV-1-infected and immune-activated individuals.
Methods
Culture, HIV-1 infection and LPS activation of macrophages
and microglia
Human peripheral blood-derived mononuclear cells were
isolated through leukopheresis from healthy donors. Hu-
man macrophages were differentiated in Dulbecco’s Modi-
fied Eagle’s Media (DMEM) (Sigma Chemical Co., St.
Louis, MO) with 10 % human serum, 50 μg/ml gentamy-
cin, 10 μg/ml ciprofloxacin (Sigma), and 1000 U/ml re-
combinant human macrophage colony-stimulating factor
(MCSF) for 7 days. The HIV-1ADA strain was used to in-
fect the macrophages at a multiplicity of infection (MOI)
of 0.1, respectively. The HIV-1ADA strain was originally
isolated from the PBMCs of an HIV-infected patient with
Kaposi’s sarcoma [52, 53]. MDM were infected with HIV-
1ADA at a multiplicity of infection (MOI) of 0.05 virus/tar-
get cell. For mock-infection, MDM were incubated with
same volume of medium without virus. After 24 h, the
culture medium was changed to remove any remnant
virus. Seven days after HIV-1-infection, culture medium
was changed to glutamine-free neurobasal medium for
24 h and supernatants were collected for subsequent RP-
HPLC or Western blot analysis. BV2 cell lines were ob-
tained from ATCC, and both cell lines were grown in
DMEM with 10 % fetal bovine serum and antibiotics.
Lipopolysaccharide (LPS) (50 ng/ml) (Sigma) was used to
immune activate BV2 cells for 24 h and supernatants were
collected for HPLC and Western blot analysis.
Rat cortical neuron cultures
Cerebral cortices were dissected from Sprague–Dawley rat
(Charles River Laboratories International Inc., Wilmington,
MA) between embryonic days 15 and 17 and triturated
with a pipet to generate cell suspension. The cell suspen-
sion was passed through a 70-μm nylon membrane (Becton
Dickinson Labware, Franklin Lakes, NJ) and then plated at
a density of 40,000 cells/well in 96-well plates pre-coated
with 5 μg/ml poly-D-lysine. The cells were then cul-
tured at 37 °C in a 5 % CO2 atmosphere for 7 days in
neurobasal medium containing B27 supplement (Life
Technologies), 0.5 mM glutamine, 100 U/ml penicillin
and 100 μg/ml streptomycin.
Ethics statement
Primary RCN were prepared in accordance with ethical
guidelines for care and use of laboratory animals set
forth by the National Institutes of Health (NIH), with In-
stitutional Animal Care and Use Committee (IACUC) #:
04-097-01; Monocytes were used in full compliance with
the University of Nebraska Medical Center and NIH eth-
ical guidelines, with the Institutional Review Board (IRB)
#: 162-93-FB. We have the informed written consent
from all participants involved in this study.
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Isolation of MVs
MVs were isolated from the supernatants of HIV-1-
infected macrophages and LPS-activated microglia through
differential centrifugations with or without neutral sphingo-
myelinases inhibitor GW4869 (Sigma) at different dosages,
2, 5 and 10 μM. Briefly, the supernatants were first centri-
fuged at 300 × g for 10 min to remove free cells, at 3000 ×
g for 20 min to remove cellular debris and then 10,000 × g
for 30 min to remove free organelles. Lastly, MVs were col-
lected by ultracentrifugation at 100,000 × g for 2 h at 4 °C.
To prepare MVs for Western blot, the MVs pellets were
lysed in M-PER mammalian protein extraction reagent
(Thermo Scientific, Pittsburgh, PA). For negative staining,
MVs were fixed in 2 % glutaraldehyde and 2 % paraformal-
dehyde. For glutaminase activity assay and neurotoxicity,
the MVs were resuspended in 1 ml of glutamine-free neu-
robasal medium.
Negative staining and electron microscopy
MVs were negatively stained with onscreen measurements.
Briefly, MVs were fixed and then spread on the silicon
monoxide and nitro-cellular film coated copper grid. The
droplets of MVs were removed with filter paper, air-dried
at room temperature and then subjected to transmission
electron microscopy (TEM) (FEI Tecnai G2 Spirit TWIN).
For the scanning electron microscope (SEM) (FEI Quanta
200), cells were fixed in 2 % glutaraldehyde and 2 % para-
formaldehyde and point dried, mounted and coated with
gold/palladium. The investigator in the EM core facility
was blinded for image acquisition and quantification.
Neurotoxicity assays
Resuspended MVs were added to neuronal cultures for
48 h with or without 10 μM of bis-2-(5-phenylacetamido-
1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) (a generous gift
presented by Dr. Tsukamoto from Colorado State Univer-
sity) and cell viability was assessed by MTT assays in 96-
well plates. MTT (Sigma) was added to the cultures to a
final concentration of 125 μg/ml. The plates were incubated
for 30 min at 37 °C with 5 % CO2 and the medium was as-
pirated. The insoluble formazan was solubilized in DMSO,
and the concentrations were determined by optical density
at 490 nm with an ELX808 densitometer (Bio-Tek Instru-
ments, Winooski, and VT). MAP2 ELISA was performed
on primary RCN cultures as previously described. Briefly,
fixed neurons were blocked with 3 % normal goat serum in
phosphate buffered saline and incubated for 2 h with anti-
bodies against MAP-2 (Millipore-Chemicon International,
Atlanta, GA), followed by anti-mouse biotinylated antibody
(Vector Laboratories, Burlingame, CA) for 1 h. Avidin/bio-
tin complex solution was added for 30 min, and then color
was developed using TMB substrate (Sigma Chemical Co.,
St. Louis, MO) and terminated with 1 M sulfuric acid
(Sigma Chemical Co., St, Louis, MO). The absorbance was
read at 450 nm using a microplate reader (Bio-Rad Labora-
tories, Hercules, CA). For morphological data that demon-
strated neuronal damage after exposed to supernatant
of HIV-1-infected macrophages or immune-activated
microglia, MAP2 immunostaining was examined by a
Nikon Eclipse TE2000E fluorescent microscope and
photographed by a digital camera (CoolSNAP EZ, Pho-
tometrics). All obtained images were imported into
Image-ProPlus, version 7.0 (Media Cybernetics, Sliver
Spring, MD) for quantifying levels of MAP2 staining.
The assessors were blinded during image acquisition or
quantification.
Western blot
Protein concentrations were determined by Bradford pro-
tein assay. SDS PAGE separated proteins from whole cell
and MVs lysates. After electrophoretically transferred to
polyvinyldifluoridene membranes (Millipore, Billerica, MA
and Bio-Rad, Hercules, CA). Membranes were incubated
overnight at 4 °C with polyclonal antibodies for GAC
(Dr. N. Curthoys, Colorado State University, Fort Collins,
CO), Alix (Santa Cruz Biotechnology, CA) and flotillin-2
(Cell Signaling Technology, Danvers, MA), followed by
horseradish peroxidase-linked secondary anti-rabbit or
anti-mouse secondary antibodies (Cell signaling Tech-
nology). Antigen-antibody complexes were visualized by
Pierce ECL Western Blotting Substrate. For quantification
of the data, films were scanned with a CanonScan 9950 F
scanner and images were analyzed using the public do-
main NIH image program (developed at the U.S. Na-
tional Institutes of Health and available on the internet
at http://rsb.info.nih.gov/nih-image/).
Analysis of glutamate and glutamine by RP-HPLC
Glutamate levels were analyzed by RP-HPLC using an
Agilent 1200 liquid chromatograph and fluorescence de-
tector as previously described [29] with a few modifica-
tions. The experiments utilized 4.6 × 75 mm, 3.5 μm
ZORBAX Eclipse AAA analytical columns (Agilent). A
gradient elution program was optimized for glutamate
measurement with a flow rate 0.75 ml/min.
Statistical analysis
Data are expressed as means ± SD unless otherwise spe-
cified. Statistical analysis was performed using ANOVA,
followed by the Tukey-post-test for paired observations.
Significance was determined by a p value < 0.05. All ex-
periments were performed with cells from at least three
donors to account for any donor-specific differences. As-
says were performed at least three times in triplicate or
quadruplicate within each assay.
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Additional files
Additional file 1: Figure S1. MVs from HIV-1-infected MDM contain
vesicular glutamate transporter. At 7 days post-infection, mock-infected
and HIV-1 infected MDM were treated with GW4869 for 24 h in serum-free
media. MVs were isolated from the supernatants and MV protein lysates were
prepared. The levels of vesicular glutamate transporter were determined by
Western blot. (TIFF 41 kb)
Additional file 2: Figure S2. HIV-1-infected macrophages induce
neurotoxicity through GLS1-containing MVs. (A-F) At 7 days post-
infection, mock-infected and HIV-1 infected macrophages were
treated with GW4869 at different dosages for 24 h. Cell-free supernatants
were collected and added to RCN cultures for neurotoxicity. DMSO was used
as solvent control for GW4869. Neurotoxic potentials of the supernatants
were determined by MAP2 fluorescent staining. Results are representative of
20 fluorescent images from three independent experiments. (TIFF 523 kb)
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